FI971742A0 - Kompetitiivisia progesteroniantagonisteja tarpeen sanelemaan raskaudenehkäisyyn naisilla - Google Patents

Kompetitiivisia progesteroniantagonisteja tarpeen sanelemaan raskaudenehkäisyyn naisilla

Info

Publication number
FI971742A0
FI971742A0 FI971742A FI971742A FI971742A0 FI 971742 A0 FI971742 A0 FI 971742A0 FI 971742 A FI971742 A FI 971742A FI 971742 A FI971742 A FI 971742A FI 971742 A0 FI971742 A0 FI 971742A0
Authority
FI
Finland
Prior art keywords
contraception
dictate
women
necessary
progesterone antagonists
Prior art date
Application number
FI971742A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI971742A7 (fi
FI971742L (fi
Inventor
Kristof Chwalisz
Klaus Stoeckemann
Karin Schmidt-Gollwitzer
Walter Klemann
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of FI971742A7 publication Critical patent/FI971742A7/fi
Publication of FI971742L publication Critical patent/FI971742L/fi
Publication of FI971742A0 publication Critical patent/FI971742A0/fi

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18Feminine contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Materials By Optical Means (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
FI971742A 1994-10-24 1995-10-24 Kompetitiivisia progesteroniantagonisteja tarpeen sanelemaan raskaudenehkäisyyn naisilla FI971742A0 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4438820 1994-10-24
PCT/EP1995/004191 WO1996012494A1 (de) 1994-10-24 1995-10-24 Kompetitive progesteronantagonisten zur bedarfsorientierten weiblichen fertilitätskontrolle

Publications (3)

Publication Number Publication Date
FI971742A7 FI971742A7 (fi) 1997-04-23
FI971742L FI971742L (fi) 1997-04-23
FI971742A0 true FI971742A0 (fi) 1997-04-23

Family

ID=6532105

Family Applications (1)

Application Number Title Priority Date Filing Date
FI971742A FI971742A0 (fi) 1994-10-24 1995-10-24 Kompetitiivisia progesteroniantagonisteja tarpeen sanelemaan raskaudenehkäisyyn naisilla

Country Status (25)

Country Link
US (1) US6143754A (cs)
EP (1) EP0787002B1 (cs)
JP (1) JPH10507461A (cs)
KR (1) KR970706827A (cs)
CN (1) CN1211087C (cs)
AT (1) ATE347894T1 (cs)
AU (1) AU707235B2 (cs)
BG (1) BG62877B1 (cs)
BR (1) BR9509478A (cs)
CA (1) CA2203541A1 (cs)
CZ (1) CZ290690B6 (cs)
DE (1) DE59511071D1 (cs)
DK (1) DK0787002T3 (cs)
ES (1) ES2279515T3 (cs)
FI (1) FI971742A0 (cs)
HU (1) HU226566B1 (cs)
IL (1) IL115738A (cs)
NO (1) NO314437B1 (cs)
NZ (1) NZ295365A (cs)
PL (1) PL319869A1 (cs)
PT (1) PT787002E (cs)
RO (1) RO120606B1 (cs)
SK (1) SK283662B6 (cs)
WO (1) WO1996012494A1 (cs)
ZA (1) ZA959008B (cs)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19745085A1 (de) * 1997-10-11 1999-04-15 Jenapharm Gmbh 11ß-Benzaldoxim-9alpha,10alpha-epoxy-estr-4-en-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Präparate
DE19809845A1 (de) * 1998-03-03 1999-09-09 Jenapharm Gmbh S-substituierte 11beta-Benzaldoxim-estra-4,9-dien-kohlensäurethiolester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische Zubereitungen
US7629334B1 (en) 1999-08-31 2009-12-08 Bayer Schering Pharma Aktiengesellschaft Mesoprogrestins (progesterone receptor modulations) as a component of compositions for hormone replacement therapy (HRT)
MXPA02002186A (es) * 1999-08-31 2002-09-02 Jenapharm Gmbh Mesoprogestinas (moduladores del receptor de progesterona) como un componente de los anticonceptivos femeninos.
PE20010581A1 (es) * 1999-08-31 2001-06-04 Schering Ag Mesoprogestinas (modulares de receptores de progesterona) como componentes de composiciones utilizadas para la terapia de sustitucion hormonal (hrt)
DE102005050729A1 (de) * 2005-10-19 2007-04-26 Schering Ag Verfahren zur präventiven bedarfsweisen hormonalen Kontrazeption
BRPI0819571A2 (pt) * 2007-12-20 2019-09-24 Teva Womenss Health Inc "método para contracepção de emergência, pacote farmacêutico para contracepção de emergência e composição farmacêutica"
EP2419109B1 (en) * 2009-04-14 2016-04-13 Laboratoire HRA-Pharma Method for on-demand contraception using levonorgestrel or norgestrel
EP2419108B1 (en) 2009-04-14 2016-08-17 Laboratoire HRA Pharma Method for on-demand contraception
MA38606A1 (fr) 2013-05-23 2017-03-31 Bayer Pharma AG Composition pharmaceutique et son utilisation, ainsi que schéma d'emploi de cette composition pharmaceutique pour la contraception à la demande
MX391191B (es) * 2014-11-17 2025-03-21 Context Biopharma Inc Composiciones de liberación extendida de onapristona y métodos.
JP2018528944A (ja) 2015-09-25 2018-10-04 コンテクスト バイオファーマ インコーポレイテッド オナプリストン中間体の製造方法
JP2019503353A (ja) * 2015-12-15 2019-02-07 コンテキスト・バイオファーマ・インコーポレイテッド 非晶質オナプリストン組成物およびそれを作製する方法
WO2018102369A1 (en) 2016-11-30 2018-06-07 Arno Therapeutics, Inc. Methods for onapristone synthesis dehydration and deprotection

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5439913A (en) * 1992-05-12 1995-08-08 Schering Aktiengesellschaft Contraception method using competitive progesterone antagonists and novel compounds useful therein

Also Published As

Publication number Publication date
NO971869L (no) 1997-04-23
EP0787002B1 (de) 2006-12-13
CZ118097A3 (en) 1997-07-16
CN1211087C (zh) 2005-07-20
ES2279515T3 (es) 2007-08-16
NO314437B1 (no) 2003-03-24
SK51897A3 (en) 1997-09-10
KR970706827A (ko) 1997-12-01
MX9703018A (es) 1997-10-31
HUT77518A (hu) 1998-05-28
JPH10507461A (ja) 1998-07-21
ATE347894T1 (de) 2007-01-15
IL115738A (en) 2002-05-23
NO971869D0 (no) 1997-04-23
WO1996012494A1 (de) 1996-05-02
SK283662B6 (sk) 2003-11-04
EP0787002A1 (de) 1997-08-06
PT787002E (pt) 2007-03-30
AU3869695A (en) 1996-05-15
DE59511071D1 (de) 2007-01-25
CZ290690B6 (cs) 2002-09-11
FI971742A7 (fi) 1997-04-23
RO120606B1 (ro) 2006-05-30
CN1161649A (zh) 1997-10-08
HU226566B1 (en) 2009-04-28
FI971742L (fi) 1997-04-23
ZA959008B (en) 1996-09-16
NZ295365A (en) 1999-07-29
DK0787002T3 (da) 2007-04-10
BR9509478A (pt) 1997-09-30
BG101427A (en) 1997-11-28
BG62877B1 (bg) 2000-10-31
PL319869A1 (en) 1997-09-01
CA2203541A1 (en) 1996-05-02
IL115738A0 (en) 1996-01-19
AU707235B2 (en) 1999-07-08
US6143754A (en) 2000-11-07

Similar Documents

Publication Publication Date Title
FI971742A0 (fi) Kompetitiivisia progesteroniantagonisteja tarpeen sanelemaan raskaudenehkäisyyn naisilla
Tietze Fertility after discontinuation of intrauterine and oral contraception
FI963049L (fi) Progesteroniantagonisteja lääkeaineiden valmistamiseksi, jotka on tarkoitettu kohdun toimintahäiriöistä johtuvien verenvuotojen hoitamiseksi
ATE217192T1 (de) Kombinationsprodukt zur kontrazeption enthaltend progesteronantagonisten und gestagenen
NO970309L (no) Anvendelse av en progesteronantagonist og av et gestagen for behandling av endometriose eller Leiomyomata uteri
PT99818A (pt) Processo de fabrico de contraceptivos orais compreendendo desogestrel 3-cetodesogestrel ou suas misturas
EP0270690A4 (en) MEDICINES FOR THE TREATMENT AND PROPHYLAXIS OF LIVER AND KIDNEY DISEASES.
NO974630D0 (no) Farmasöytisk kombinasjonspreparat for hormonell antikonsepsjon
ATE198707T1 (de) Prostaglandinanaloga zur oralen oder vaginalen verabreichung in der routinebehandlung des dritten stadiums der geburtswehen
Szontagh et al. Post-coital contraception with dienoestrol
Board et al. Sequential oral contraception using DMAP
Tyler Studies of" mini-micro" contraceptive doses of a new progestrogen
HUP9900313A1 (hu) Antiösztrogének alkalmazása hím nemzőképesség szabályozására
Asbjorn et al. Low dose of gestagen as a contraceptive method. A clinical trial
Suran Ovulation inhibition with sequential therapy. A continuing clinical study of fertility control
PT1150683E (pt) Utilizacao de dienogest em doses elevadas
Balin et al. Low dosage megestrol acetate application as contraceptive
Crist Post-coital estrogen
ES395365A1 (es) Procedimiento para la obtencion de agentes anticonceptivos.
KR960705553A (ko) 원하지 않는 고통을 멈추기 위한 니트로글리세린의 투약 방법
UA41777A (uk) Препарат для переривання вагітності ранніх термінів в амбулаторних умовах